Skip to main content
. Author manuscript; available in PMC: 2010 Aug 17.
Published in final edited form as: J Immunol. 2010 Feb 19;184(6):2974–2984. doi: 10.4049/jimmunol.0803478

Figure 6. TSLP blockade inhibits Th2-type CHS and DC accumulation in skin draining lymph nodes.

Figure 6

(a) WT mice were treated with TSLP blocking antibody (clone M702) on the day before (200 μg IV) and the day of (100 μg IP) FITC sensitization. Mice received similar anti-TSLP treatments on days 6 and 7, followed by FITC challenge on day 7. Ear swelling was measured 24 H post challenge (*P<0.05, **P<0.01, one-way ANOVA, n=5 mice per group). (b) To determine the effect of anti-TSLP treatment on FITC+ DC accumulation in the skin draining lymph nodes, a similar sensitization and antibody treatment was used, with an additional anti-TSLP treatment at 8 H post sensitization. 24 H post sensitization mice were sacrificed and FITC+ DC populations were analyzed in the skin draining lymph nodes. (c) Frequency of FITC+CD11c+ cells in the skin draining lymph nodes of anti-TSLP treated WT mice 24 H post FITC sensitization.